PharmOptima appoints business development director

Ophthalmology specialist hires Rick Coulon

PharmOptima, a US contract research organisation (CRO) with expertise in conducting drug metabolism and pharmacokinetic (DMPK) studies for ophthalmology products, has appointed Rick Coulon as director of business development.

Coulon has more than 20 years of sales, marketing and business development experience within the pharmaceutical industry. Although his background includes a broad list of therapeutic specialities, his strength is in ocular drug development.

Coulon has previously worked at Ciba Vision (Novartis), Akorn, Mallinckrodt Pharmaceuticals, Stonebridge Pharma (GSK), Auriga Laboratories and CCG Partners.

You may also like

Manufacturing

Lonza opens capsule drug development-focused site at its Colmar facility

The new addition to the French site will allow customers access to experts and technologies ideal for capsule formulation and development
Research & Development

Adenosine A2a receptor: novel biophysical fragment screening using polymer-encapsulated nanodiscs

Fragment screening is a useful method for hit identification as it offers an efficient and flexible way to identify novel therapeutic starting points that other techniques may have missed because of the small molecular size of the fragments
Research & Development

Roche's antiviral Xofluza reduces flu transmission in Phase III trial

Topline results suggest that Xofluza could be used to reduce the transmission of seasonal influenza
Research & Development

RSSL opens 3D imaging and metrology laboratory for end-to-end research and analysis

The laboratory will offer, micro-CT, microscopy and spectroscopy services for its pharmaceutical and medical device partners
Manufacturing

Ensuring cGMP compliance in cell and gene therapy manufacturing

3P discusses how companies can scale up their CGT manufacturing protocols while remaining compliant with stringent global regulations
Manufacturing

Quotient Sciences and Vasa Therapeutics announce dosing of first subjects in VS-041 novel heart failure trial

The trial is designed to evaluate the safety, tolerability, and pharmacokinetics of VS-041 in healthy volunteers
Research & Development

How excipient testing allows for safe pharmaceutical manufacturing

Excipients play a fundamental role in API delivery, and John Welch, Butterworth's Associate Director of Business Operations, believes that their testing is key to ensuring the safety of pharmaceutical products
Subscribe now